Where is Mendus located?

Mendus is headquartered in Stockholm, Sweden.

How many employees does Mendus have?

As of Apr 30, 2026, the latest employee count at Mendus is 25.

Is Mendus a funded company?

Mendus is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Mendus rank among its competitors?

Mendus ranks 1918th amongst 3292 active competitors, of which 1129 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Mendus?

Mendus' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Mendus - 2026 Company Profile, Funding & Competitors

Company Details

Developer of cell-based therapies for cancer treatment. It offers allogeneic dendritic cell-based medicine, including Vididencel for acute myeloid leukemia, and ovarian cancer, and Ilixadencel for solid tumors.

Website: mendus.com
Social
Email ID: *****@mendus.com
Phone Number: +46 **********

Key Metrics

Founded Year

2002

Location

Stockholm, Sweden

Stage

Funding Raised

Investors

Van Herk Groep

Ranked

1918^th among 3292 active competitors

Employee Count

25 as on Apr 30, 2026

Investment & Acquisitions

DCprime

Similar Companies

Jazz Pharmaceuticals & 3060 more

View Mendus' full profile

Mendus is a funded company. Mendus has 1 institutional investor.

View details of Mendus's funding rounds and investors

Mendus' employee count trend

Mendus has 25 employees as of Apr 26. Here is Mendus's employee count trend over the years:

Uncover Mendus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mendus include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Mendus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
1918th	Mendus 2002, Stockholm (Sweden), Funding Raised	Developer of cell-based therapies for cancer treatment	-	Van Herk Groep	29/100